Raised B-type natriuretic peptide predicts implantable cardioverter- defibrillator therapy in patients with ischaemic cardiomyopathy [4]

Heart

Volumn 92, Issue 9, 2006, Pages 1323-1324

  Klingenberg, Roland ^a   Zugck, C ^a   Becker, R ^a   Schellberg, D ^a   Heinze, G ^b   Kell, R ^a   Remppis, A ^a   Schoels, W ^a   Katus, H A ^a   Dengler, T J ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

CONTROLLED STUDY; DEFIBRILLATOR; DIURETIC ACTIVITY; HEART DEATH; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; LETTER; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION; TACHYCARDIA;

EID: 33748072422     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.076117     Document Type: Letter

References (5)

1. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-80.
2. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
3. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
4. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
5. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000;102:611-6.